News
Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...
EQS-News: Berliner Effektengesellschaft AG / Schlagwort (e): Halbjahresbericht Berliner Effektengesellschaft veröffentlicht Konzern-Halbjahresbericht 15.08.2025 / 18:24 CET/CEST Für den Inhalt der ...
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...
TipRanks on MSN7h
CureVac reports Q2 revenue EUR 1.2M vs. EUR 14.4M last year
By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...
TipRanks on MSN7h
CureVac sees cash runway into 2028
Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the ...
CureVac has a strong cash position of €392.7 million as of June 30, 2025, with an expected cash runway into 2028. Revenues ...
New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...
NEW YORK (dpa-AFX) - Das Analysehaus Jefferies hat das Kursziel für Adyen ( Adyen BV Parts Sociales) nach dem jüngsten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback